Form 4: Alumis Inc. Director Increases Stake Following ACELYRIN Merger Completion

Alumis Inc. Director Srinivas Akkaraju reported an acquisition of 1,214,582 shares of common stock on May 21, 2025, as part of the merger with ACELYRIN, Inc., increasing his indirect beneficial ownership to 4,801,370 shares.

Summary

• Srinivas Akkaraju, a Director of Alumis Inc. (ALMS), reported a change in beneficial ownership via a Form 4 filing.
• On May 21, 2025, Mr. Akkaraju acquired 1,214,582 shares of Alumis Inc. common stock.
• This acquisition was a direct result of the merger between Alumis Inc. and ACELYRIN, Inc., which became effective on May 21, 2025.
• Under the merger terms, each share of ACELYRIN common stock was exchanged for 0.4814 shares of Alumis Inc. common stock.
• The acquired shares were received in exchange for 2,523,022 shares of ACELYRIN common stock previously held.
• Following this transaction, Mr. Akkaraju's indirect beneficial ownership in Alumis Inc. totals 4,801,370 shares, held through Samsara BioCapital, L.P.

Sentiment

Score: 7

Explanation: The completion of a merger and a director's increased stake (even if through exchange) can be viewed positively as it signifies strategic execution and alignment of interests. However, a Form 4 itself doesn't provide operational or financial performance details to gauge overall sentiment.

Positives

• The completion of the merger with ACELYRIN, Inc. signifies the successful execution of a strategic corporate action.
• A director's increased beneficial ownership, even if through a non-cash merger exchange, can be interpreted as a positive signal of confidence in the combined entity's future prospects.

Future Outlook

The document primarily reports a past transaction related to a merger and does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic direction beyond the completion of the merger.

Industry Context

This Form 4 indicates the completion of a merger between Alumis Inc. and ACELYRIN, Inc., suggesting consolidation or strategic expansion within the biotechnology or pharmaceutical industry. Such mergers are common for companies seeking to expand their pipeline, market reach, or intellectual property.

Comparison to Industry Standards

• This document is a Form 4, which reports insider trading activity, specifically a change in beneficial ownership due to a merger. It does not contain financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects. The transaction reflects the mechanics of a merger rather than a performance benchmark.

Related Party Transactions

• The shares are held indirectly by Samsara BioCapital, L.P. ('Samsara LP'). The reporting person, Srinivas Akkaraju, as the managing member of Samsara BioCapital GP, LLC (the general partner of Samsara LP), shares voting and investment authority over these shares. This constitutes a related party relationship for beneficial ownership disclosure.

Stakeholder Impact

• Shareholders of Alumis Inc. are impacted by the completion of the merger, which alters the company's structure and potentially its future value proposition.
• Employees of ACELYRIN, Inc. are now part of the combined Alumis Inc. entity, which may affect their roles and organizational structure.
• The transaction aligns the interests of a key director with the long-term success of the combined company through increased equity ownership.

Next Steps

• Integration of ACELYRIN, Inc. as a wholly-owned subsidiary of Alumis Inc.
• Potential future disclosures related to the combined entity's financial performance and strategic plans.

Key Dates

Keywords

Alumis Inc., ALMS, ACELYRIN Inc., Merger, Form 4, Beneficial Ownership, Srinivas Akkaraju, Samsara BioCapital, Director, Equity Acquisition